{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:15:22Z","timestamp":1789085722051,"version":"build-2803163510"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer is a disease characterized by genomic instability and aberrant DNA repair. Poly (ADP-ribose) polymerase-1 (PARP-1) represents a well-established therapeutic target, particularly in ovarian and prostate cancer. However, the currently approved PARP inhibitors face challenges such as resistance, toxicity, and reduced efficacy. The search for alternative scaffolds has therefore become increasingly urgent. In this study, we used an integrated approach combining computer-aided methods to search for potential lead compounds among emodin-based anthraquinone derivatives as PARP-1 inhibitors. Using a PASS-based QSAR approach, drug-likeness prediction, and in silico ADMET assessment, we pre-screened a large set of anthraquinones and identified several potential hits for interaction with PARP-1. These hits were studied using molecular docking with the PARP-1 catalytic domain (PDB ID: 7KK4). The most stable and compact complexes were further explored by 500\u00a0ns molecular dynamics (MD) simulations and various dynamic properties (RMSD, RMSF, Rg, SASA, MolSA, hydrogen bonds, PCA, DCCM). The key finding of this study is that several emodin-derived anthraquinones exhibited binding behavior and ADMET profiles comparable to, or better than, the reference PARP-1 inhibitor. Among them, CID-10425624 emerged as the most promising candidate, exhibiting stable binding, reduced conformational fluctuation, compact complex formation, persistent hydrogen-bond interactions, and enhanced dynamic residue correlations within the PARP-1 catalytic domain. These findings suggest that the anthraquinone scaffold can provide a valuable starting point for developing structurally distinct PARP-1 inhibitors. In summary, this study identified several emodin-derived anthraquinones, particularly CID-10425624, as computationally prioritized lead candidates for PARP-1 inhibition, providing a novel anthraquinone-based scaffold for further experimental validation and optimization.<\/jats:p>","DOI":"10.1038\/s41598-026-55381-4","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:33:16Z","timestamp":1782012796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computational discovery of emodin-based anthraquinones as PARP-1 inhibitors with relevance to ovarian and prostate cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Sohag","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Reaz","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrato","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla All","family":"Maruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Nasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monotosh Kumar","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Shanta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubel","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash Chandra","family":"Shaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmoy Kumar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Shafiqul Islam","family":"Sovon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahmida","family":"Akter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al Noman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Ashok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Jeyabalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Shing","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vetriselvan","family":"Subramaniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"55381_CR1","volume":"5","author":"Y Yao","year":"2014","unstructured":"Yao, Y. & Dai, W. Genomic instability and cancer. J. Carcinog. Mutagen. 5, 1000165 (2014).","journal-title":"J. Carcinog. Mutagen."},{"key":"55381_CR2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030486","volume":"9","author":"MJ Schiewer","year":"2019","unstructured":"Schiewer, M. J. & Knudsen, K. E. DNA damage response in prostate cancer. Cold Spring Harb. Perspect. Med. 9, a030486 (2019).","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"3","key":"55381_CR3","volume":"2022","author":"G Liu","year":"2020","unstructured":"Liu, G. et al. Small molecule inhibitors targeting the cancers. MedComm 2022(3), e181 (2020).","journal-title":"MedComm"},{"key":"55381_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10741-9","volume":"10","author":"M-C Caron","year":"2019","unstructured":"Caron, M.-C. et al. Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nat. Commun. 10, 2954 (2019).","journal-title":"Nat. Commun."},{"key":"55381_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","volume":"11","author":"X Fu","year":"2023","unstructured":"Fu, X. et al. Mechanism of PARP inhibitor resistance and potential overcoming strategies. Genes Dis. 11, 306\u2013320 (2023).","journal-title":"Genes Dis."},{"key":"55381_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose, M. et al. PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance. Front. Cell Dev. Biol. 8, 564601 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"55381_CR7","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.3390\/molecules28155849","volume":"28","author":"MG Nizi","year":"2023","unstructured":"Nizi, M. G., Sarnari, C. & Tabarrini, O. Privileged scaffolds for potent and specific inhibitors of mono-ADP-ribosylating PARPs. Molecules 28, 5849 (2023).","journal-title":"Molecules"},{"key":"55381_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3329\/dujps.v24i1.82415","volume":"24","author":"MR Uddin","year":"2025","unstructured":"Uddin, M. R. et al. Withaferin A and its derivatives as potential anti-cancer drug lead candidates: An in-silico drug design. Dhaka Univ. J. Pharm. Sci. 24, 105\u2013120 (2025).","journal-title":"Dhaka Univ. J. Pharm. Sci."},{"key":"55381_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nexres.2025.101280","volume":"5","author":"MR Uddin","year":"2026","unstructured":"Uddin, M. R. et al. Identification of natural inhibitors targeting MMP-9 via network pharmacology and advanced molecular modeling approaches. Next Res. 5, 101280 (2026).","journal-title":"Next Res."},{"key":"55381_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.71193\/jpci.20250014","volume":"2","author":"DR Sobuj","year":"2025","unstructured":"Sobuj, D. R. et al. Assessment of phytochemical screening, antimicrobial, antioxidant, and thrombolytic potential of ethanolic leaf extract of Clerodendrum indicum. JPCI 2, 1\u201310 (2025).","journal-title":"JPCI"},{"key":"55381_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/biomedicines12010201","volume":"12","author":"P Chunarkar-Patil","year":"2024","unstructured":"Chunarkar-Patil, P. et al. Anticancer drug discovery based on natural products: From computational approaches to clinical studies. Biomedicines 12, 201 (2024).","journal-title":"Biomedicines"},{"key":"55381_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28248139","volume":"28","author":"L Zhao","year":"2023","unstructured":"Zhao, L. & Zheng, L. A review on bioactive anthraquinone and derivatives as the regulators for ROS. Molecules 28, 8139 (2023).","journal-title":"Molecules"},{"key":"55381_CR13","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.13005\/bpj\/3066","volume":"17","author":"J Anjum","year":"2024","unstructured":"Anjum, J. et al. Exploration of the GLUT-4 modulation potential of Gynura procumbens as a mechanism behind its antidiabetic activity. Biomed. Pharmacol. J. 17, 2759\u20132768 (2024).","journal-title":"Biomed. Pharmacol. J."},{"key":"55381_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.biomed.2012.03.003","volume":"2","author":"S-C Hsu","year":"2012","unstructured":"Hsu, S.-C. & Chung, J.-G. Anticancer potential of emodin. Biomedicine 2, 108\u2013116 (2012).","journal-title":"Biomedicine"},{"key":"55381_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13020-021-00509-z","volume":"16","author":"Q Zheng","year":"2021","unstructured":"Zheng, Q. et al. Advances in the study of emodin: An update on pharmacological properties and mechanistic basis. Chin. Med. 16, 102 (2021).","journal-title":"Chin. Med."},{"key":"55381_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28041829","volume":"28","author":"F Yan","year":"2023","unstructured":"Yan, F. et al. In silico investigation of the molecular mechanism of PARP1 inhibition for the treatment of BRCA-deficient cancers. Molecules 28, 1829 (2023).","journal-title":"Molecules"},{"key":"55381_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056284","volume":"8","author":"Y-R Lee","year":"2013","unstructured":"Lee, Y.-R. et al. New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small molecules. PLoS ONE 8, e56284 (2013).","journal-title":"PLoS ONE"},{"key":"55381_CR18","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1248\/bpb.b21-00508","volume":"44","author":"C-Y Yiu","year":"2021","unstructured":"Yiu, C.-Y., Chiu, Y.-J. & Lin, T.-P. The ethyl acetate subfraction of Polygonum cuspidatum root containing emodin affect EBV gene expression and induce EBV-positive cells apoptosis. Biol. Pharm. Bull. 44, 1837\u20131842 (2021).","journal-title":"Biol. Pharm. Bull."},{"key":"55381_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.3892\/or.2015.3744","volume":"33","author":"SY Hwang","year":"2015","unstructured":"Hwang, S. Y. et al. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. Oncol. Rep. 33, 1691\u20131698 (2015).","journal-title":"Oncol. Rep."},{"key":"55381_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"SA Hollingsworth","year":"2018","unstructured":"Hollingsworth, S. A. & Dror, R. O. Molecular dynamics simulation for all. Neuron 99, 1129\u20131143 (2018).","journal-title":"Neuron"},{"key":"55381_CR21","first-page":"1","volume":"21","author":"J Aghajani","year":"2022","unstructured":"Aghajani, J. et al. Molecular dynamic simulations and molecular docking as a potential way for designed new inhibitor drug without resistance. Tanaffos 21, 1\u201314 (2022).","journal-title":"Tanaffos"},{"key":"55381_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16101328","volume":"16","author":"DR Serrano","year":"2024","unstructured":"Serrano, D. R. et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics 16, 1328 (2024).","journal-title":"Pharmaceutics"},{"key":"55381_CR23","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.3390\/molecules28104123","volume":"28","author":"O-L Moldovan","year":"2023","unstructured":"Moldovan, O.-L. et al. Identification of some glutamic acid derivatives with biological potential by computational methods. Molecules 28, 4123 (2023).","journal-title":"Molecules"},{"key":"55381_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski, C. A. Lead- and drug-like compounds: The rule-of-five revolution. Drug. Discov. Today. Technol. 1, 337\u2013341 (2004).","journal-title":"Drug. Discov. Today. Technol."},{"key":"55381_CR25","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s13318-017-0417-y","volume":"42","author":"M Mikov","year":"2017","unstructured":"Mikov, M. et al. The role of drug metabolites in the inhibition of Cytochrome P450 enzymes. Eur. J. Drug Metab. Pharmacokinet. 42, 881\u2013890 (2017).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"55381_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1517\/17425255.2010.482930","volume":"6","author":"B Feng","year":"2010","unstructured":"Feng, B. et al. Renal clearance in drug discovery and development: Molecular descriptors, drug transporters and disease state. Expert Opin. Drug Metab. Toxicol. 6, 939\u2013952 (2010).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"55381_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0305-7372(95)90024-1","volume":"21","author":"E Fuse","year":"1995","unstructured":"Fuse, E. et al. Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: Integration of pharmacokinetics with pharmacodynamics and toxicodynamics. Cancer Treat. Rev. 21, 133\u2013157 (1995).","journal-title":"Cancer Treat. Rev."},{"key":"55381_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.compbiolchem.2016.01.005","volume":"61","author":"N Basant","year":"2016","unstructured":"Basant, N., Gupta, S. & Singh, K. P. Predicting human intestinal absorption of diverse chemicals using ensemble learning based QSAR modeling approaches. Comput. Biol. Chem. 61, 178\u2013196 (2016).","journal-title":"Comput. Biol. Chem."},{"key":"55381_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13321-021-00580-6","volume":"14","author":"M Wei","year":"2022","unstructured":"Wei, M. et al. HobPre: Accurate prediction of human oral bioavailability for small molecules. J. Cheminform. 14, 1 (2022).","journal-title":"J. Cheminform."},{"key":"55381_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s11095-013-1222-1","volume":"31","author":"MT Kim","year":"2014","unstructured":"Kim, M. T. et al. Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches. Pharm. Res. 31, 1002\u20131014 (2014).","journal-title":"Pharm. Res."},{"key":"55381_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122004","volume":"624","author":"N Panse","year":"2022","unstructured":"Panse, N. & Gerk, P. M. The Caco-2 Model: Modifications and enhancements to improve efficiency and predictive performance. Int. J. Pharm. 624, 122004 (2022).","journal-title":"Int. J. Pharm."},{"key":"55381_CR32","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1016\/j.csbj.2024.08.002","volume":"23","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Investigation of in silico studies for cytochrome P450 isoforms specificity. Comput. Struct. Biotechnol. J. 23, 3090\u20133103 (2024).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"55381_CR33","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1021\/acs.jcim.3c02030","volume":"64","author":"J Fan","year":"2024","unstructured":"Fan, J. et al. Predicting elimination of small-molecule drug half-life in pharmacokinetics using ensemble and consensus machine learning methods. J. Chem. Inf. Model. 64, 3080\u20133092 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"55381_CR34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"55381_CR35","doi-asserted-by":"publisher","DOI":"10.2196\/14232","volume":"1","author":"SS Butt","year":"2020","unstructured":"Butt, S. S. et al. Molecular docking using Chimera and Autodock Vina software for nonbioinformaticians. JMIR Bioinform. Biotechnol. 1, e14232 (2020).","journal-title":"JMIR Bioinform. Biotechnol."},{"key":"55381_CR36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/acs.jchemed.5b00404","volume":"93","author":"C Zardecki","year":"2016","unstructured":"Zardecki, C. et al. RCSB Protein Data Bank: A resource for chemical, biochemical, and structural explorations of large and small biomolecules. J. Chem. Educ. 93, 569\u2013575 (2016).","journal-title":"J. Chem. Educ."},{"key":"55381_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136631","volume":"10","author":"Y-H Huang","year":"2015","unstructured":"Huang, Y.-H., Rose, P. W. & Hsu, C.-N. Citing a data repository: A case study of the Protein Data Bank. PLoS ONE 10, e0136631 (2015).","journal-title":"PLoS ONE"},{"key":"55381_CR38","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1021\/acs.jcim.0c00057","volume":"60","author":"H Guterres","year":"2020","unstructured":"Guterres, H. & Im, W. Improving protein-ligand docking results with high-throughput molecular dynamics simulations. J. Chem. Inf. Model. 60, 2189\u20132198 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"55381_CR39","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.1216338","volume":"336","author":"M-F Langelier","year":"2012","unstructured":"Langelier, M.-F. et al. Structural basis for DNA-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336, 728\u2013732 (2012).","journal-title":"Science"},{"key":"55381_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jsb.2011.09.006","volume":"179","author":"Z Yang","year":"2012","unstructured":"Yang, Z. et al. UCSF Chimera, MODELLER, and IMP: An integrated modeling system. J. Struct. Biol. 179, 269\u2013278 (2012).","journal-title":"J. Struct. Biol."},{"key":"55381_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290176","volume":"18","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level. PLoS ONE 18, e0290176 (2023).","journal-title":"PLoS ONE"},{"key":"55381_CR42","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s11172-019-2683-0","volume":"68","author":"VV Poroikov","year":"2019","unstructured":"Poroikov, V. V. et al. Computer-aided prediction of biological activity spectra for organic compounds: The possibilities and limitations. Russ. Chem. Bull. 68, 2143\u20132154 (2019).","journal-title":"Russ. Chem. Bull."},{"key":"55381_CR43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bioinformatics\/16.8.747","volume":"16","author":"A Lagunin","year":"2000","unstructured":"Lagunin, A. et al. PASS: Prediction of activity spectra for biologically active substances. Bioinformatics 16, 747\u2013748 (2000).","journal-title":"Bioinformatics"},{"key":"55381_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/0929867033368510","volume":"10","author":"AV Stepanchikova","year":"2003","unstructured":"Stepanchikova, A. V. et al. Prediction of biological activity spectra for substances: Evaluation on the diverse sets of drug-like structures. Curr. Med. Chem. 10, 225\u2013233 (2003).","journal-title":"Curr. Med. Chem."},{"key":"55381_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-28195-z","volume":"15","author":"AEM Elayyan","year":"2025","unstructured":"Elayyan, A. E. M. et al. Identification of bioactive phytoconstituents as promising ABL2 inhibitors using virtual screening and molecular dynamics simulation. Sci Rep 15, 44528 (2025).","journal-title":"Sci Rep"},{"key":"55381_CR46","doi-asserted-by":"publisher","first-page":"49639","DOI":"10.1021\/acsomega.4c07808","volume":"9","author":"HN Suha","year":"2024","unstructured":"Suha, H. N. et al. Evaluating the anticancer properties of novel piscidinol a derivatives: Insights from DFT, molecular docking, and molecular dynamics studies. ACS Omega 9, 49639\u201349661 (2024).","journal-title":"ACS Omega"},{"key":"55381_CR47","unstructured":"Use of molecular docking computational tools in drug discovery. In Progress in Medicinal Chemistry, 273\u2013343 (Elsevier)."},{"key":"55381_CR48","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"L Ferreira","year":"2015","unstructured":"Ferreira, L. et al. Molecular docking and structure-based drug design strategies. Molecules 20, 13384\u201313421 (2015).","journal-title":"Molecules"},{"key":"55381_CR49","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"key":"55381_CR50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.016573","author":"K Ryan","year":"2021","unstructured":"Ryan, K. et al. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.RA120.016573 (2021).","journal-title":"J. Biol. Chem."},{"key":"55381_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"55381_CR52","volume":"2011","author":"F Khalil","year":"2011","unstructured":"Khalil, F. & L\u00e4er, S. Physiologically based pharmacokinetic modeling: Methodology, applications, and limitations with a focus on its role in pediatric drug development. J. Biomed. Biotechnol. 2011, 907461 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"55381_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2025.108626","volume":"120","author":"JPB Arango","year":"2026","unstructured":"Arango, J. P. B. et al. In silico evaluation of pharmacokinetic properties and molecular docking for the identification of potential anticancer compounds. Comput. Biol. Chem. 120, 108626 (2026).","journal-title":"Comput. Biol. Chem."},{"key":"55381_CR54","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim, S. et al. PubChem substance and compound databases. Nucleic Acids Res. 44, D1202\u2013D1213 (2016).","journal-title":"Nucleic Acids Res."},{"key":"55381_CR55","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fchem.2020.00726","volume":"8","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Computational approaches in preclinical studies on drug discovery and development. Front. Chem. 8, 726 (2020).","journal-title":"Front. Chem."},{"key":"55381_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-015-0067-5","volume":"7","author":"WP Feinstein","year":"2015","unstructured":"Feinstein, W. P. & Brylinski, M. Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets. J. Cheminform. 7, 18 (2015).","journal-title":"J. Cheminform."},{"key":"55381_CR57","doi-asserted-by":"crossref","unstructured":"Lee, S., Wang, D., Seeliger, M. A. et al. Calculating protein-ligand residence times through state predictive information bottleneck based enhanced sampling. bioRxiv. 2024.04.16.589710 (2024).","DOI":"10.1101\/2024.04.16.589710"},{"key":"55381_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.rineng.2025.104491","volume":"25","author":"NS Sawaran Singh","year":"2025","unstructured":"Sawaran Singh, N. S. et al. Effect of atomic porosity on the mechanical properties of aluminium polycrystalline using molecular dynamics simulation. Results Eng. 25, 104491 (2025).","journal-title":"Results Eng."},{"key":"55381_CR59","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.1016\/j.csbj.2025.11.034","volume":"27","author":"JDD Cediel-Becerra","year":"2025","unstructured":"Cediel-Becerra, J. D. D., Silva, J. C. F. & Dias, R. EquilibraTor streamlines molecular dynamics simulations in a single execution. Comput. Struct. Biotechnol. J. 27, 5318\u20135325 (2025).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"55381_CR60","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1021\/acs.jafc.1c06110","volume":"70","author":"A Vidal-Limon","year":"2022","unstructured":"Vidal-Limon, A., Aguilar-Toal\u00e1, J. E. & Liceaga, A. M. Integration of molecular docking analysis and molecular dynamics simulations for studying food proteins and bioactive peptides. J. Agric. Food Chem. 70, 934\u2013943 (2022).","journal-title":"J. Agric. Food Chem."},{"key":"55381_CR61","doi-asserted-by":"publisher","DOI":"10.1063\/5.0040966","volume":"154","author":"AC Simmonett","year":"2021","unstructured":"Simmonett, A. C. & Brooks, B. R. A compression strategy for particle mesh Ewald theory. J. Chem. Phys. 154, 054112 (2021).","journal-title":"J. Chem. Phys."},{"key":"55381_CR62","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess, B. et al. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463\u20131472 (1997).","journal-title":"J. Comput. Chem."},{"key":"55381_CR63","doi-asserted-by":"crossref","unstructured":"Jensen, L. E., Rao, S., Schuschnig, M. et al. Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery. Sci. Adv. 8, eadd1436.","DOI":"10.1126\/sciadv.add1436"},{"key":"55381_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1208\/s12249-022-02229-5","volume":"23","author":"ME Soliman","year":"2022","unstructured":"Soliman, M. E. et al. Simulation models for prediction of bioavailability of medicinal drugs-the interface between experiment and computation. AAPS PharmSciTech 23, 86 (2022).","journal-title":"AAPS PharmSciTech"},{"key":"55381_CR65","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4155\/fmc-2020-0294","volume":"13","author":"RW Brown","year":"2021","unstructured":"Brown, R. W. Abiotic scaffolds in medicinal chemistry: Not a waste of chemical space. Future Med. Chem. 13, 211\u2013224 (2021).","journal-title":"Future Med. Chem."},{"key":"55381_CR66","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DEV Pires","year":"2015","unstructured":"Pires, D. E. V., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066\u20134072 (2015).","journal-title":"J. Med. Chem."},{"key":"55381_CR67","doi-asserted-by":"publisher","first-page":"W469","DOI":"10.1093\/nar\/gkae254","volume":"52","author":"Y Myung","year":"2024","unstructured":"Myung, Y., de S\u00e1, A. G. C. & Ascher, D. B. Deep-PK: Deep learning for small molecule pharmacokinetic and toxicity prediction. Nucleic Acids Res. 52, W469\u2013W475 (2024).","journal-title":"Nucleic Acids Res."},{"key":"55381_CR68","volume":"3","author":"A Sultana","year":"2026","unstructured":"Sultana, A. et al. Exploring the therapeutic potential of Premna obtusifolia and Oxalis corniculata: A combined in vitro bioassay and molecular docking study. JMNP 3, 100003 (2026).","journal-title":"JMNP"},{"key":"55381_CR69","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.vascn.2013.07.004","volume":"68","author":"E Sevin","year":"2013","unstructured":"Sevin, E. et al. Accelerated Caco-2 cell permeability model for drug discovery. J. Pharmacol. Toxicol. Methods 68, 334\u2013339 (2013).","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"55381_CR70","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/pharmaceutics15112523","volume":"15","author":"M Kus","year":"2023","unstructured":"Kus, M., Ibragimow, I. & Piotrowska-Kempisty, H. Caco-2 cell line standardization with pharmaceutical requirements and in vitro model suitability for permeability assays. Pharmaceutics 15, 2523 (2023).","journal-title":"Pharmaceutics"},{"key":"55381_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15112599","volume":"15","author":"SK Niazi","year":"2023","unstructured":"Niazi, S. K. Non-invasive drug delivery across the blood\u2013brain barrier: A prospective analysis. Pharmaceutics 15, 2599 (2023).","journal-title":"Pharmaceutics"},{"key":"55381_CR72","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1021\/acs.molpharmaceut.8b00785","volume":"15","author":"R Watanabe","year":"2018","unstructured":"Watanabe, R. et al. Predicting fraction unbound in human plasma from chemical structure: Improved accuracy in the low value ranges. Mol. Pharm. 15, 5302\u20135311 (2018).","journal-title":"Mol. Pharm."},{"key":"55381_CR73","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.tips.2020.03.004","volume":"41","author":"M Davies","year":"2020","unstructured":"Davies, M. et al. Improving the accuracy of predicted human pharmacokinetics: Lessons learned from the AstraZeneca drug pipeline over two decades. Trends Pharmacol. Sci. 41, 390\u2013408 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"55381_CR74","doi-asserted-by":"crossref","unstructured":"Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review, https:\/\/www.mdpi.com\/2227-9059\/12\/7\/1467 (Accessed 10 Jan 2026).","DOI":"10.3390\/biomedicines12071467"},{"key":"55381_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090846","volume":"12","author":"M Deodhar","year":"2020","unstructured":"Deodhar, M. et al. Mechanisms of CYP450 inhibition: Understanding drug-drug interactions due to mechanism-based inhibition in clinical practice. Pharmaceutics 12, 846 (2020).","journal-title":"Pharmaceutics"},{"key":"55381_CR76","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1021\/jm2001629","volume":"54","author":"Y Kido","year":"2011","unstructured":"Kido, Y., Matsson, P. & Giacomini, K. M. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J. Med. Chem. 54, 4548\u20134558 (2011).","journal-title":"J. Med. Chem."},{"key":"55381_CR77","doi-asserted-by":"publisher","first-page":"F56","DOI":"10.1152\/ajprenal.00486.2012","volume":"304","author":"JN Harper","year":"2013","unstructured":"Harper, J. N. & Wright, S. H. Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am. J. Physiol. Renal Physiol. 304, F56\u2013F67 (2013).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"55381_CR78","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","volume":"61","author":"DA Smith","year":"2018","unstructured":"Smith, D. A. et al. Relevance of half-life in drug design. J. Med. Chem. 61, 4273\u20134282 (2018).","journal-title":"J. Med. Chem."},{"key":"55381_CR79","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/07391102.2006.10507118","volume":"24","author":"CHTP Silva","year":"2006","unstructured":"Silva, C. H. T. P. & Taft, C. A. ADMET properties, database screening, molecular dynamics, density functional, and docking studies of novel potential anti-cancer compounds. J. Biomol. Struct. Dyn. 24, 263\u2013268 (2006).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"55381_CR80","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/jat.4354","volume":"42","author":"M Xu","year":"2022","unstructured":"Xu, M. et al. In silico prediction of chemical aquatic toxicity by multiple machine learning and deep learning approaches. J. Appl. Toxicol. 42, 1766\u20131776 (2022).","journal-title":"J. Appl. Toxicol."},{"key":"55381_CR81","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1039\/C4TX00174E","volume":"4","author":"L Sun","year":"2015","unstructured":"Sun, L. et al. In silico prediction of chemical aquatic toxicity with chemical category approaches and substructural alerts. Toxicol. Res. 4, 452\u2013463 (2015).","journal-title":"Toxicol. Res."},{"key":"55381_CR82","first-page":"73","volume":"6","author":"S David","year":"2010","unstructured":"David, S. & Hamilton, J. P. Drug-induced liver injury. US Gastroenterol. Hepatol. Rev. 6, 73\u201380 (2010).","journal-title":"US Gastroenterol. Hepatol. Rev."},{"key":"55381_CR83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s43094-025-00788-5","volume":"11","author":"AK Saleh","year":"2025","unstructured":"Saleh, A. K. et al. Exploring drug-induced liver injury: Comprehensive insights into mechanisms and management of hepatotoxic agents. Futur. J. Pharm. Sci. 11, 38 (2025).","journal-title":"Futur. J. Pharm. Sci."},{"key":"55381_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2021.130681","volume":"280","author":"A Gajewicz-Skretna","year":"2021","unstructured":"Gajewicz-Skretna, A. et al. Generating accurate in silico predictions of acute aquatic toxicity for a range of organic chemicals: Towards similarity-based machine learning methods. Chemosphere 280, 130681 (2021).","journal-title":"Chemosphere"},{"key":"55381_CR85","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jmgm.2013.08.006","volume":"45","author":"AA Antolin","year":"2013","unstructured":"Antolin, A. A. et al. Exploring the effect of PARP-1 flexibility in docking studies. J. Mol. Graph. Model. 45, 192\u2013201 (2013).","journal-title":"J. Mol. Graph. Model."},{"key":"55381_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae081","volume":"25","author":"H Wang","year":"2024","unstructured":"Wang, H. Prediction of protein\u2013ligand binding affinity via deep learning models. Brief. Bioinform. 25, bbae081 (2024).","journal-title":"Brief. Bioinform."},{"key":"55381_CR87","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1021\/acs.jcim.8b00261","volume":"58","author":"P-C Do","year":"2018","unstructured":"Do, P.-C., Lee, E. H. & Le, L. Steered molecular dynamics simulation in rational drug design. J. Chem. Inf. Model. 58, 1473\u20131482 (2018).","journal-title":"J. Chem. Inf. Model."},{"key":"55381_CR88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/pr9010071","volume":"9","author":"OMH Salo-Ahen","year":"2020","unstructured":"Salo-Ahen, O. M. H. et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9, 71 (2020).","journal-title":"Processes"},{"key":"55381_CR89","volume":"17","author":"JO Uhomoibhi","year":"2022","unstructured":"Uhomoibhi, J. O. et al. Molecular modeling identification of potential drug candidates from selected African plants against SARS-CoV-2 key druggable proteins. Sci. Afr. 17, e01279 (2022).","journal-title":"Sci. Afr."},{"key":"55381_CR90","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-1-62703-658-0_11","volume":"1084","author":"CC David","year":"2014","unstructured":"David, C. C. & Jacobs, D. J. Principal component analysis: A method for determining the essential dynamics of proteins. Methods Mol. Biol. 1084, 193\u2013226 (2014).","journal-title":"Methods Mol. Biol."},{"key":"55381_CR91","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/bioinformatics\/btaa018","volume":"36","author":"JL Vel\u00e1zquez-Libera","year":"2020","unstructured":"Vel\u00e1zquez-Libera, J. L. et al. LigRMSD: A web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking. Bioinformatics 36, 2912\u20132914 (2020).","journal-title":"Bioinformatics"},{"key":"55381_CR92","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s12033-023-00831-x","volume":"66","author":"AM da Fonseca","year":"2024","unstructured":"da Fonseca, A. M. et al. Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2 via molecular docking, and approach with molecular dynamics, RMSD, RMSF, H-Bond, SASA and MMGBSA. Mol. Biotechnol. 66, 1919\u20131933 (2024).","journal-title":"Mol. Biotechnol."},{"key":"55381_CR93","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1039\/D1ME00053E","volume":"6","author":"K Konstantinidis","year":"2021","unstructured":"Konstantinidis, K. et al. On the estimation of the molecular inaccessible volume and the molecular accessible surface of a ligand in protein\u2013ligand systems. Mol. Syst. Des. Eng. 6, 946\u2013963 (2021).","journal-title":"Mol. Syst. Des. Eng."},{"key":"55381_CR94","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.str.2011.03.010","volume":"19","author":"JA Marsh","year":"2011","unstructured":"Marsh, J. A. & Teichmann, S. A. Relative solvent accessible surface area predicts protein conformational changes upon binding. Structure 19, 859\u2013867 (2011).","journal-title":"Structure"},{"key":"55381_CR95","doi-asserted-by":"crossref","unstructured":"Shukla, R. & Tripathi, T. Molecular dynamics simulation of protein and protein\u2013ligand complexes. In Computer-Aided Drug Design (ed Singh, D. B. ed) 133\u2013161 (Springer).","DOI":"10.1007\/978-981-15-6815-2_7"},{"key":"55381_CR96","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1021\/acs.jctc.7b00028","volume":"13","author":"K Sargsyan","year":"2017","unstructured":"Sargsyan, K., Grauffel, C. & Lim, C. How molecular size impacts RMSD applications in molecular dynamics simulations. J. Chem. Theory Comput. 13, 1518\u20131524 (2017).","journal-title":"J. Chem. Theory Comput."},{"key":"55381_CR97","doi-asserted-by":"publisher","first-page":"100880","DOI":"10.1016\/j.imu.2022.100880","volume":"29","author":"TI Adelusi","year":"2022","unstructured":"Adelusi, T. I. et al. Molecular modeling in drug discovery. Inform. Med. Unlocked 29, 100880 (2022).","journal-title":"Inform. Med. Unlocked"},{"key":"55381_CR98","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1107\/S2059798316013218","volume":"72","author":"JJ Tanner","year":"2016","unstructured":"Tanner, J. J. Empirical power laws for the radii of gyration of protein oligomers. Acta Crystallogr. D. Struct. Biol. 72, 1119\u20131129 (2016).","journal-title":"Acta Crystallogr. D. Struct. Biol."},{"key":"55381_CR99","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1134\/S0026893308040195","volume":"42","author":"MYu Lobanov","year":"2008","unstructured":"Lobanov, MYu., Bogatyreva, N. S. & Galzitskaya, O. V. Radius of gyration as an indicator of protein structure compactness. Mol. Biol. 42, 623\u2013628 (2008).","journal-title":"Mol. Biol."},{"key":"55381_CR100","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1021\/jp807701h","volume":"113","author":"Y Deng","year":"2009","unstructured":"Deng, Y. & Roux, B. Computations of standard binding free energies with molecular dynamics simulations. J. Phys. Chem. B. 113, 2234\u20132246 (2009).","journal-title":"J. Phys. Chem. B."},{"key":"55381_CR101","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1016\/j.csbj.2024.10.051","volume":"23","author":"A Sethi","year":"2024","unstructured":"Sethi, A., Agrawal, N. & Brezovsky, J. Impact of water models on the structure and dynamics of enzyme tunnels. Comput. Struct. Biotechnol. J. 23, 3946\u20133954 (2024).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"55381_CR102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-1-4939-9752-7_7","volume":"2053","author":"G Bitencourt-Ferreira","year":"2019","unstructured":"Bitencourt-Ferreira, G., Veit-Acosta, M. & de Azevedo, W. F. Hydrogen bonds in protein-ligand complexes. Methods. Mol. Biol. 2053, 93\u2013107 (2019).","journal-title":"Methods. Mol. Biol."},{"key":"55381_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e42595","volume":"11","author":"M Faruque","year":"2025","unstructured":"Faruque, M. et al. Investigating small molecules in propolis as Nipah virus glycoprotein (NiV-G) inhibitors through molecular interaction studies. Heliyon 11, e42595 (2025).","journal-title":"Heliyon"},{"key":"55381_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229730","volume":"15","author":"GRC Pereira","year":"2020","unstructured":"Pereira, G. R. C. et al. In silico analysis of the tryptophan hydroxylase 2 (TPH2) protein variants related to psychiatric disorders. PLoS ONE 15, e0229730 (2020).","journal-title":"PLoS ONE"},{"key":"55381_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109245","volume":"183","author":"S Moradi","year":"2024","unstructured":"Moradi, S. et al. A review on description dynamics and conformational changes of proteins using combination of principal component analysis and molecular dynamics simulation. Comput. Biol. Med. 183, 109245 (2024).","journal-title":"Comput. Biol. Med."},{"key":"55381_CR106","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.drudis.2017.01.005","volume":"22","author":"A Giuliani","year":"2017","unstructured":"Giuliani, A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov. Today 22, 1069\u20131076 (2017).","journal-title":"Drug Discov. Today"},{"key":"55381_CR107","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jmb.2008.10.018","volume":"385","author":"GG Maisuradze","year":"2009","unstructured":"Maisuradze, G. G., Liwo, A. & Scheraga, H. A. Principal component analysis for protein folding dynamics. J. Mol. Biol. 385, 312\u2013329 (2009).","journal-title":"J. Mol. Biol."},{"key":"55381_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29051144","volume":"29","author":"A Salamat","year":"2024","unstructured":"Salamat, A. et al. SAR, molecular docking and molecular dynamic simulation of natural inhibitors against SARS-CoV-2 Mpro spike protein. Molecules 29, 1144 (2024).","journal-title":"Molecules"},{"key":"55381_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032394","volume":"7","author":"M Hansen","year":"2012","unstructured":"Hansen, M. et al. pcaGoPromoter\u2013An R package for biological and regulatory interpretation of principal components in genome-wide gene expression data. PLoS ONE 7, e32394 (2012).","journal-title":"PLoS ONE"},{"key":"55381_CR110","first-page":"84","volume":"14","author":"IJ dos Santos Nascimento","year":"2022","unstructured":"dos Santos Nascimento, I. J. et al. Dynamic cross-correlation matrix (DCCM) reveals new insights to discover new NLRP3 inhibitors useful as anti-inflammatory drugs. Med. Sci. Forum 14, 84 (2022).","journal-title":"Med. Sci. Forum"},{"key":"55381_CR111","doi-asserted-by":"publisher","first-page":"13497","DOI":"10.1080\/07391102.2021.1989040","volume":"40","author":"M Kumari","year":"2022","unstructured":"Kumari, M., Singh, R. & Subbarao, N. Exploring the interaction mechanism between potential inhibitor and multi-target Mur enzymes of Mycobacterium tuberculosis using molecular docking, molecular dynamics simulation, principal component analysis, free energy landscape, dynamic cross-correlation matrices, vector movements, and binding free energy calculation. J. Biomol. Struct. Dyn. 40, 13497\u201313526 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"55381_CR112","unstructured":"Yu, H. & Dalby, P. A. A beginner\u2019s guide to molecular dynamics simulations and the identification of cross-correlation networks for enzyme engineering. In Methods in Enzymology, 15\u201349 (Elsevier)."},{"key":"55381_CR113","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/carcin\/bgr300","volume":"33","author":"MTW Teo","year":"2012","unstructured":"Teo, M. T. W. et al. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis 33, 581\u2013586 (2012).","journal-title":"Carcinogenesis"},{"key":"55381_CR114","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/dna.2009.0969","volume":"29","author":"M Wang","year":"2010","unstructured":"Wang, M. et al. Genetic variants of XRCC1, APE1, and ADPRT genes and risk of bladder cancer. DNA Cell Biol. 29, 303\u2013311 (2010).","journal-title":"DNA Cell Biol."},{"key":"55381_CR115","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11596-015-1466-6","volume":"35","author":"B Liang","year":"2015","unstructured":"Liang, B. et al. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells. J. Huazhong Univ. Sci. Technol. [Med Sci] 35, 535\u2013540 (2015).","journal-title":"J. Huazhong Univ. Sci. Technol. [Med Sci]"},{"key":"55381_CR116","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.canlet.2021.08.001","volume":"520","author":"M Xu","year":"2021","unstructured":"Xu, M. et al. Landscape analysis of lncRNAs shows that DDX11-AS1 promotes cell-cycle progression in liver cancer through the PARP1\/p53 axis. Cancer Lett. 520, 282\u2013294 (2021).","journal-title":"Cancer Lett."},{"key":"55381_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112755","volume":"13","author":"Y-G Cherng","year":"2021","unstructured":"Cherng, Y.-G. et al. Induced mitochondrial alteration and DNA damage via IFNGR-JAK2-STAT1-PARP1 pathway facilitates viral hepatitis associated hepatocellular carcinoma aggressiveness and stemness. Cancers 13, 2755 (2021).","journal-title":"Cancers"},{"key":"55381_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2023.110567","volume":"382","author":"R Gong","year":"2023","unstructured":"Gong, R. et al. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer. Chem. Biol. Interact. 382, 110567 (2023).","journal-title":"Chem. Biol. Interact."},{"key":"55381_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202737","volume":"10","author":"T Yang","year":"2023","unstructured":"Yang, T. et al. The PRMT6\/PARP1\/CRL4B complex regulates the circadian clock and promotes breast tumorigenesis. Adv. Sci. 10, 2202737 (2023).","journal-title":"Adv. Sci."},{"key":"55381_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116054","volume":"265","author":"X Li","year":"2024","unstructured":"Li, X. et al. Dual target PARP1\/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy. Eur. J. Med. Chem. 265, 116054 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"55381_CR121","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1158\/0008-5472.CAN-22-1740","volume":"83","author":"L-L Long","year":"2023","unstructured":"Long, L.-L. et al. PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer. Cancer Res. 83, 568\u2013581 (2023).","journal-title":"Cancer Res."},{"key":"55381_CR122","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2111915","volume":"11","author":"P Juncheng","year":"2022","unstructured":"Juncheng, P. et al. PARP1 inhibition elicits immune responses against non-small cell lung cancer. Oncoimmunology 11, 2111915 (2022).","journal-title":"Oncoimmunology"},{"key":"55381_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102231","volume":"52","author":"CM Roggero","year":"2025","unstructured":"Roggero, C. M. et al. CDK4\/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer. Transl. Oncol. 52, 102231 (2025).","journal-title":"Transl. Oncol."},{"key":"55381_CR124","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1002\/cam4.4034","volume":"10","author":"X Ji","year":"2021","unstructured":"Ji, X. et al. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer. Cancer Med. 10, 4743\u20134751 (2021).","journal-title":"Cancer Med."},{"key":"55381_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150943","volume":"738","author":"J Rajawat","year":"2024","unstructured":"Rajawat, J. & Banerjee, M. Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer. Biochem. Biophys. Res. Commun. 738, 150943 (2024).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"55381_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092092","volume":"13","author":"M IJff","year":"2021","unstructured":"IJff, M. et al. PARP1-inhibition sensitizes cervical cancer cell lines for chemoradiation and thermoradiation. Cancers 13, 2092 (2021).","journal-title":"Cancers"},{"key":"55381_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.804962","author":"F Wang","year":"2022","unstructured":"Wang, F. et al. PARP1 upregulation in recurrent oral cancer and treatment resistance. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/fcell.2021.804962 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"55381_CR128","doi-asserted-by":"publisher","DOI":"10.1177\/1536012117723786","volume":"16","author":"S Kossatz","year":"2017","unstructured":"Kossatz, S., Weber, W. & Reiner, T. Detection and delineation of oral cancer with a PARP1-targeted optical imaging agent. Mol. Imaging 16, 1536012117723786 (2017).","journal-title":"Mol. Imaging"},{"key":"55381_CR129","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2217\/fon.14.313","volume":"11","author":"CC Gunderson","year":"2015","unstructured":"Gunderson, C. C. & Moore, K. N. Olaparib: An oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer. Future Oncol. 11, 747\u2013757 (2015).","journal-title":"Future Oncol."},{"key":"55381_CR130","first-page":"1635","volume":"22","author":"A Vaculov\u00e1","year":"2002","unstructured":"Vaculov\u00e1, A. et al. Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells. Anticancer Res. 22, 1635\u20131639 (2002).","journal-title":"Anticancer Res."},{"key":"55381_CR131","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/carcin\/bgn118","volume":"29","author":"M Schwab","year":"2008","unstructured":"Schwab, M. et al. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 29, 1407\u20131414 (2008).","journal-title":"Carcinogenesis"},{"key":"55381_CR132","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3892\/ijmm.2015.2125","volume":"35","author":"B Zheng","year":"2015","unstructured":"Zheng, B., Chai, R. & Yu, X. Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest through the caspase-3 and PARP pathways. Int. J. Mol. Med. 35, 1317\u20131322 (2015).","journal-title":"Int. J. Mol. Med."},{"key":"55381_CR133","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41388-024-02943-3","volume":"43","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3\/WNT\/\u03b2-catenin signalling pathway. Oncogene 43, 866\u2013883 (2024).","journal-title":"Oncogene"},{"key":"55381_CR134","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1541-7786.MCR-18-1369","volume":"18","author":"M Xiao","year":"2020","unstructured":"Xiao, M. et al. Let-7e suppresses DNA damage repair and sensitizes ovarian cancer to Cisplatin through targeting PARP1. Mol. Cancer Res. 18, 436\u2013447 (2020).","journal-title":"Mol. Cancer Res."},{"key":"55381_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.931445","author":"W-W Zuo","year":"2022","unstructured":"Zuo, W.-W. et al. High expression of PARP1 in tumor and stroma cells predicts different prognosis and platinum resistance in patients with advanced epithelial ovarian cancer. Front. Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.931445 (2022).","journal-title":"Front. Oncol."},{"key":"55381_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02360-9","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Macrocarpal I induces immunogenic cell death and synergizes with immune checkpoint inhibition by targeting tubulin and PARP1 in colorectal cancer. Cell Death Discov. 11, 73 (2025).","journal-title":"Cell Death Discov."},{"key":"55381_CR137","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.canlet.2021.06.029","volume":"520","author":"Z Jing","year":"2021","unstructured":"Jing, Z. et al. NCAPD2 inhibits autophagy by regulating Ca2+\/CAMKK2\/AMPK\/mTORC1 pathway and PARP-1\/SIRT1 axis to promote colorectal cancer. Cancer Lett. 520, 26\u201337 (2021).","journal-title":"Cancer Lett."},{"key":"55381_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.772","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. FTO promotes colorectal cancer progression and chemotherapy resistance via demethylating G6PD\/PARP1. Clin. Transl. Med. 12, e772 (2022).","journal-title":"Clin. Transl. Med."},{"key":"55381_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113669","volume":"155","author":"F Qui\u00f1onero","year":"2022","unstructured":"Qui\u00f1onero, F. et al. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Biomed. Pharmacother. 155, 113669 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"55381_CR140","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","volume":"19","author":"H Zhu","year":"2020","unstructured":"Zhu, H. et al. PARP inhibitors in pancreatic cancer: Molecular mechanisms and clinical applications. Mol. Cancer 19, 49 (2020).","journal-title":"Mol. Cancer"},{"key":"55381_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-76850-4","volume":"10","author":"T Viera","year":"2020","unstructured":"Viera, T. & Patidar, P. L. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition. Sci. Rep. 10, 20210 (2020).","journal-title":"Sci. Rep."},{"key":"55381_CR142","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s11033-021-06169-4","volume":"48","author":"R Zhou","year":"2021","unstructured":"Zhou, R. et al. PARP1 rs1136410 C\/C genotype associated with an increased risk of esophageal cancer in smokers. Mol. Biol. Rep. 48, 1485\u20131491 (2021).","journal-title":"Mol. Biol. Rep."},{"key":"55381_CR143","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.31557\/APJCP.2020.21.10.2987","volume":"21","author":"R-M Zhou","year":"2020","unstructured":"Zhou, R.-M. et al. PARP1 gene polymorphisms and the prognosis of esophageal cancer patients from Cixian high-incidence region in Northern China. Asian Pac. J. Cancer Prev. 21, 2987\u20132992 (2020).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"55381_CR144","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/cas.12322","volume":"105","author":"T Nasuno","year":"2014","unstructured":"Nasuno, T. et al. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci. 105, 202\u2013210 (2014).","journal-title":"Cancer Sci."},{"key":"55381_CR145","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11307-022-01746-w","volume":"24","author":"F Dehdashti","year":"2022","unstructured":"Dehdashti, F. et al. Pilot study: PARP1 imaging in advanced prostate cancer. Mol. Imaging Biol. 24, 853\u2013861 (2022).","journal-title":"Mol. Imaging Biol."},{"key":"55381_CR146","doi-asserted-by":"publisher","unstructured":"Lai, Y., Kong, Z., Zeng, T. et al. PARP1-siRNA suppresses human prostate cancer cell growth and progression. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2018.6238. (Epub ahead of print 26 January 2018).","DOI":"10.3892\/or.2018.6238"},{"key":"55381_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04288-z","volume":"21","author":"M Huang","year":"2023","unstructured":"Huang, M. et al. PARP1 negatively regulates transcription of BLM through its interaction with HSP90AB1 in prostate cancer. J. Transl. Med. 21, 445 (2023).","journal-title":"J. Transl. Med."},{"key":"55381_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.719192","author":"H Li","year":"2021","unstructured":"Li, H. et al. PARP1 inhibitor combined with Oxaliplatin efficiently suppresses Oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway. Front. Cell Dev. Biol. https:\/\/doi.org\/10.3389\/fcell.2021.719192 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"55381_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.04.033","author":"X Zhu","year":"2026","unstructured":"Zhu, X. et al. Circular RNA circATM binds PARP1 to suppress Wnt\/\u03b2-catenin signaling and induce cell cycle arrest in gastric cancer cells. J. Adv. Res. https:\/\/doi.org\/10.1016\/j.jare.2025.04.033 (2026) (Epub ahead of print 25 April 2025).","journal-title":"J. Adv. Res."},{"key":"55381_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2019.152472","volume":"215","author":"H Afzal","year":"2019","unstructured":"Afzal, H. et al. PARP1: A potential biomarker for gastric cancer. Pathol. Res. Pract. 215, 152472 (2019).","journal-title":"Pathol. Res. Pract."},{"key":"55381_CR151","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.eururo.2022.05.013","volume":"82","author":"J Lanillos","year":"2022","unstructured":"Lanillos, J. et al. Interrogating the significance of PARP1 expression and PBRM1 mutation as biomarkers for predicting the response to Atezolizumab plus Bevacizumab or to Sunitinib in patients with Clear Cell Renal Cell Carcinoma. Eur. Urol. 82, 334\u2013335 (2022).","journal-title":"Eur. Urol."},{"key":"55381_CR152","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.urolonc.2020.04.004","volume":"39","author":"P Makhov","year":"2021","unstructured":"Makhov, P. et al. Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers. Urol. Oncol. 39, 312\u2013315 (2021).","journal-title":"Urol. Oncol."},{"key":"55381_CR153","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.eururo.2021.09.024","volume":"81","author":"M Hagiwara","year":"2022","unstructured":"Hagiwara, M. et al. The significance of PARP1 as a biomarker for predicting the response to PD-L1 blockade in patients with PBRM1-mutated clear cell renal cell carcinoma. Eur. Urol. 81, 145\u2013148 (2022).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55381-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55381-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55381-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:03:35Z","timestamp":1789085015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55381-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55381"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55381-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28375"}}